As of Mar 16
| +0.05 / +0.10%|
The 30 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 56.97, with a high estimate of 72.88 and a low estimate of 32.92. The median estimate represents a +12.94% increase from the last price of 50.44.
The current consensus among 31 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.